Working… Menu

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01795586
Recruitment Status : Active, not recruiting
First Posted : February 20, 2013
Last Update Posted : July 13, 2021
Eisai Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 24, 2015
Estimated Study Completion Date : December 2021